ATC Group: C01E Other cardiac preparations

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01E in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01E Other cardiac preparations

Group C01E contents

Code Title
C01EA Prostaglandins
C01EB Other cardiac preparations
C01EX Other cardiac combination products

Active ingredients in C01E

Active Ingredient

Transthyretin amyloid cardiomyopathy is initiated by the dissociation of the transthyretin (TTR) tetramer into its constituent monomers. Acoramidis is a specific stabiliser of TTR. Acoramidis was designed to mimic the disease protective genetic variant (T119M), through the formation of hydrogen bonds with adjacent serine residues within both thyroxine binding sites of the tetramer.

Adenosine is a purine nucleoside which is present in all cells of the body. Animal pharmacology studies have in several species shown that adenosine has a negative dromotropic effect on the atrioventricular (AV) node.

Alprostadil is chemically identical to prostaglandin E1, the actions of which include vasodilatation of blood vessels in the erectile tissues of the corpora cavernosa and increase in cavernosal artery blood flow, causing penile rigidity.

Ibuprofen is a propionic acid derivative NSAID that has demonstrated its efficacy by inhibition of prostaglandin synthesis. In humans ibuprofen reduces inflammatory pain, swellings and fever. Furthermore, ibuprofen reversibly inhibits platelet aggregation.

Indometacin has anti-inflammatory, antipyretic, and analgesic effects, it is an inhibitor of prostaglandin synthetase.

Ivabradine is a pure heart rate lowering agent, acting by selective and specific inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate. The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarisation.

Mavacamten is a selective, allosteric, and reversible cardiac myosin inhibitor. Mavacamten modulates the number of myosin heads that can enter power-generating states, thus reducing (or in HCM normalizing) the probability of force-producing systolic and residual diastolic cross-bridge formation. Mavacamten also shifts the overall myosin population towards an energy-sparing, but recruitable, super-relaxed state. In HCM patients, cardiac myosin inhibition with mavacamten normalises contractility, reduces dynamic LVOT obstruction, and improves cardiac filling pressures.

Meldonium is a structural analogue of a precursor of carnitine, gamma-butyrobetaine (GBB), which has one carbon atom replaced by nitrogen atom. Meldonium, by reversibly inhibiting the activity of gamma butyrobetainhydroxylase, causes a decrease of carnitine biosynthesis and thus prevents long-chain fatty acid transport through the cell membranes. Accordingly, it prevents the accumulation of strong detergents, activated forms of un-oxidised fatty acids, in cells thus diminishing damage of the cells membranes.

Ranolazine may have some antianginal effects by inhibition of the late sodium current in cardiac cells. This reduces intracellular sodium accumulation and consequently decreases intracellular calcium overload. Ranolazine, via its action to decrease the late sodium current, is considered to reduce these intracellular ionic imbalances during ischaemia. This reduction in cellular calcium overload is expected to improve myocardial relaxation and thereby decrease left ventricular diastolic stiffness.

Regadenoson is a low affinity agonist (Ki ≈ 1.3 μM) for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor (Ki >16.5 μM), and very low, if any, affinity for the A2B and A3 adenosine receptors. Activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow (CBF).

In patients with ischaemic heart disease, trimetazidine acts as a metabolic agent, preserving the myocardial high-energy phosphate intracellular levels.

Related product monographs

Document Type Information Source  
 ADENOCARD Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 ADENOCOR Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ADENOSCAN Solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 BEYONTTRA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 CAMZYOS Hard capsule MPI, EU: SmPC European Medicines Agency (EU)
 CORLENTOR Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 INDOCID Capsules MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 INDOCID Suppositories MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PEDEA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 PROCORALAN Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 PROSTIN VR Concentrate for solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 RANEXA Prolonged-release tablet MPI, EU: SmPC European Medicines Agency (EU)
 RAPISCAN Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 VASTAREL MPI, EU: SmPC Health Products Regulatory Authority (IE)